Microbiome Therapeutics Market (By Type: FMT, Microbiome Drugs; By Application: C. difficile, Crohn's Disease, Inflammatory Bowel Disease, Diabetes) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Microbiome Therapeutics Market 

5.1. COVID-19 Landscape: Microbiome Therapeutics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Microbiome Therapeutics Market, By Type

8.1. Microbiome Therapeutics Market, by Type, 2022-2030

8.1.1. FMT

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Microbiome Drugs

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Microbiome Therapeutics Market, By Application

9.1. Microbiome Therapeutics Market, by Application, 2022-2030

9.1.1. C. difficile

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Crohn’s disease

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Inflammatory Bowel Disease

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Diabetes

9.1.4.1. Market Revenue and Forecast (2017-2030)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Microbiome Therapeutics Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Type (2017-2030)

10.1.2. Market Revenue and Forecast, by Application (2017-2030)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Type (2017-2030)

10.1.3.2. Market Revenue and Forecast, by Application (2017-2030)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Type (2017-2030)

10.1.4.2. Market Revenue and Forecast, by Application (2017-2030)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Type (2017-2030)

10.2.2. Market Revenue and Forecast, by Application (2017-2030)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Type (2017-2030)

10.2.3.2. Market Revenue and Forecast, by Application (2017-2030)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Type (2017-2030)

10.2.4.2. Market Revenue and Forecast, by Application (2017-2030)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Type (2017-2030)

10.2.5.2. Market Revenue and Forecast, by Application (2017-2030)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Type (2017-2030)

10.2.6.2. Market Revenue and Forecast, by Application (2017-2030)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Type (2017-2030)

10.3.2. Market Revenue and Forecast, by Application (2017-2030)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Type (2017-2030)

10.3.3.2. Market Revenue and Forecast, by Application (2017-2030)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Type (2017-2030)

10.3.4.2. Market Revenue and Forecast, by Application (2017-2030)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Type (2017-2030)

10.3.5.2. Market Revenue and Forecast, by Application (2017-2030)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Type (2017-2030)

10.3.6.2. Market Revenue and Forecast, by Application (2017-2030)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Type (2017-2030)

10.4.2. Market Revenue and Forecast, by Application (2017-2030)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Type (2017-2030)

10.4.3.2. Market Revenue and Forecast, by Application (2017-2030)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Type (2017-2030)

10.4.4.2. Market Revenue and Forecast, by Application (2017-2030)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Type (2017-2030)

10.4.5.2. Market Revenue and Forecast, by Application (2017-2030)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Type (2017-2030)

10.4.6.2. Market Revenue and Forecast, by Application (2017-2030)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Type (2017-2030)

10.5.2. Market Revenue and Forecast, by Application (2017-2030)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Type (2017-2030)

10.5.3.2. Market Revenue and Forecast, by Application (2017-2030)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Type (2017-2030)

10.5.4.2. Market Revenue and Forecast, by Application (2017-2030)

Chapter 11. Company Profiles

11.1. OpenBiome

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Seres Therapeutics Inc.

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. 4D Pharma plc.

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Locus Biosciences, Inc.

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. LTE Scientific

11.5. Enterome SA

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Finch Therapeutics Group, Inc.

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Intralytix, Inc.

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Microbiotica

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Second Genome

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Rebiotix Inc.

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Report Details

  • Report Code:39454
  • Category:Healthcare
  • No. of Pages:150+
  • Format:PDF/PPT/Excel
  • Published:August 2022
  • Historical Year:2021-2022
  • Base Year:2023
  • Estimated Year:2024-2033

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers